About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

UNKNOWNPhase 2

XELOX+Bevacizumab and XELIRI + Bevacizumab Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer

A Randomized, Open, Controlled, Multicenter,Phase II Clinical Trial of XELOX+Bevacizumab and XELIRI + Bevacizumab Alternative Regimen as First-line Treatment for Advanced Colorectal Cancer

NCT03511183•Harbin Medical University

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Colorectal NeoplasmsChemotherapy

Interventions

XELIRI + bevacizumab

XELOX + bevacizumab

Locations

1

China

Locations (1)

Harbin Medical University

Harbin, Heilongjiang, China

Key Dates

Start Date

March 1, 2018

Primary Completion Date

December 1, 2019

Completion Date

June 1, 2020

Last Updated

May 1, 2018

Related Studies

RECRUITINGPhase 3

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

NCT06662786

Colorectal Neoplasms

RECRUITINGPhase 1

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

NCT06663319

Colorectal NeoplasmsGastrointestinal Neoplasms

RECRUITINGPhase 3

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)

NCT05239741

Colorectal Neoplasms

RECRUITINGPhase 3

Study on the Efficacy and Safety of Mecobalamin in Preventing Taxane-related Peripheral Neuropathy

NCT07423390

Peripheral Neuropathy Due to ChemotherapyPeripheral Neuropathy, Chemotherapy-induced

Comparing the Effects of Art Therapy and Mandala Application on State Anxiety Levels in Chemotherapy Patients

NCT07435597

Oncologic DiseaseChemotherapy

Feasibility and Acceptability of the Remote Oncology Symptom Assessment Application

NCT07218874

CancerSolid Tumor Cancer+1 more

View all related studies

Contacts

Yu Han, doctor

CONTACT

+86-451-86298303 hanyuemail@163.com

Sponsors

Lead Sponsor

Harbin Medical University

Collaborators

Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Fudan University
Sun Yat-sen University
First Affiliated Hospital of Harbin Medical University
The Second Affiliated Hospital of Harbin Medical University
Liaoning Cancer Hospital & Institute
Shengjing Hospital
The First Hospital of Jilin University
The First Affiliated Hospital of Dalian Medical University
Jilin Provincial Tumor Hospital
Jinzhou Medical University

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 1, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions